Neoadjuvant Tislelizumab Plus Chemotherapy for Resectable Locally-advanced Head and Neck Squamous Cell Carcinoma
Tongji Hospital
Tongji Hospital
Fudan University
Fudan University
Changhai Hospital
Infinity Pharmaceuticals, Inc.
Hunan Cancer Hospital
Tianjin Medical University Cancer Institute and Hospital
Ruijin Hospital
Ludwig-Maximilians - University of Munich
The First Affiliated Hospital with Nanjing Medical University
Zhongshan Hospital Xiamen University
Xijing Hospital
IRCCS San Raffaele
ChineseAMS
Fudan University
Fudan University
Ruijin Hospital
Australasian Gastro-Intestinal Trials Group
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Shengjing Hospital
The First Hospital of Jilin University
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Tianjin Medical University Cancer Institute and Hospital
Tianjin Medical University Cancer Institute and Hospital
Sichuan Cancer Hospital and Research Institute
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Huazhong University of Science and Technology
Tianjin Medical University Cancer Institute and Hospital
Nagoya University
Fudan University
Peking Union Medical College Hospital
Peking Union Medical College Hospital
Guangdong Association of Clinical Trials
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
ChineseAMS
Wakayama Medical University
Henan Provincial People's Hospital
ChineseAMS
Fuzhou General Hospital
Jilin University
ChineseAMS
Peking University
Chinese PLA General Hospital
Barwon Health
Chinese PLA General Hospital
Tongji University
Chinese PLA General Hospital
ChineseAMS
Zhejiang University
University of Tennessee Cancer Institute